BASEL, Switzerland,
Feb. 16 /PRNewswire/ - Neuro-Biotech
Corp. (PINKSHEET: MRES) (OTCQB: MRES) is pleased to provide its
shareholders additional details about the unsolicited offer. The
conditions to be met are as follows:
- AURIC Pharma Science will provide financial statements proving
its ability to complete the purchase.
- AURIC Pharma Science will provide detailed distribution network
of its products and services.
- Neuro-Biotech Corp. will provide patent information on all its
exclusive products and services.
- Neuro-Biotech Corp. will provide all previous and effected
purchase orders, as well as future pending orders.
Both companies will also be signing a
Non-Disclosure Agreement for certain areas of their due diligence
but Neuro-Biotech Corp. intends on disclosing all possible
information to its shareholders along the process.
For more information on Neuro-Biotech Corp or to
contact a company representative, please visit:
www.neuro-biotechcorp.com
FORWARD LOOKING STATEMENTS
This release contains statements that are made
pursuant to the Safe Harbor Provisions of the Private Securities
Litigation Act of 1995. Certain statements in this press release
may contain words such as "anticipates," "believes," "could,"
"expects," "intends," "may," "projects," "targets" and other
similar language that is considered forward-looking statements.
These forward-looking statements are subject to certain risks and
uncertainties and persons reading this release are cautioned that
such statements are only predictions, and that the Company's actual
future results or performance may be materially different. The
Company disclaims any intention or obligation to update or revise
forward-looking information, whether as a result of new
information, future events, or otherwise, could cause the company's
actual results to differ materially from those indicated in any
forward-looking statements.
SOURCE Neuro-Biotech Corp.
Copyright . 16 PR Newswire